Form4insider filings, from the source

SEC Form 4/A · accession 0001104659-16-163806

CRISPR Therapeutics AG · CRSP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owners
Period of report
Oct 24, 2016
Accepted (ET)
Dec 23, 2016 · 6:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Oct 24, 2016C437,247—A676,895IFootnote
Common StockF2Oct 24, 2016C3,100,477—A3,777,372IFootnote
Common StockF2Oct 24, 2016C231,077—A4,008,449IFootnote
Common StockF2Oct 24, 2016P95,596$14.00A4,104,045IFootnote
Common StockF2,F3Oct 24, 2016C2,754—A2,754IFootnote
Common StockF2,F3Oct 24, 2016C19,524—A22,278IFootnote
Common StockF2,F3Oct 24, 2016C1,454—A23,732IFootnote
Common StockF3Oct 24, 2016P602$14.00A24,334IFootnote
Common StockF2,F4Oct 24, 2016C2,210,417—A2,210,417IFootnote
Common StockF2,F4Oct 24, 2016C173,167—A2,383,584IFootnote
Common StockF4Oct 24, 2016P60,219$14.00A2,443,803IFootnote
Common StockF2,F5Oct 24, 2016C66,490—A66,490IFootnote
Common StockF2,F5Oct 24, 2016C5,210—A71,700IFootnote
Common StockF2,F6Oct 24, 2016C168,224—A168,224IFootnote
Common StockF2,F6Oct 24, 2016C13,180—A181,404IFootnote
Common StockF6Oct 24, 2016P4,583$14.00A185,987IFootnote
Common StockF2,F7Oct 24, 2016C73,704—A73,704IFootnote
Common StockF2,F7Oct 24, 2016C5,774—A79,478IFootnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A-1 Preferred SharesF1,F2—Oct 24, 2016C437,247D——Common Stock437,2470I
Series A-1 Preferred SharesF1,F3—Oct 24, 2016C2,754D——Common Stock2,7540I
Series A-2 Preferred SharesF1,F2—Oct 24, 2016C3,100,477D——Common Stock3,100,4770I
Series A-2 Preferred SharesF1,F3—Oct 24, 2016C19,524D——Common Stock19,5240I
Series A-3 Preferred SharesF1,F4—Oct 24, 2016C2,210,417D——Common Stock2,210,4170I
Series A-3 Preferred SharesF1,F5—Oct 24, 2016C66,490D——Common Stock66,4900I
Series A-3 Preferred SharesF1,F6—Oct 24, 2016C168,224D——Common Stock168,2240I
Series A-3 Preferred SharesF1,F7—Oct 24, 2016C73,704D——Common Stock73,7040I
Series B Preferred SharesF1,F2—Oct 24, 2016C231,077D——Common Stock231,0770I
Series B Preferred SharesF1,F3—Oct 24, 2016C1,454D——Common Stock1,4540I
Series B Preferred SharesF1,F4—Oct 24, 2016C173,167D——Common Stock173,1670I
Series B Preferred SharesF1,F5—Oct 24, 2016C5,210D——Common Stock5,2100I
Series B Preferred SharesF1,F6—Oct 24, 2016C13,180D——Common Stock13,1800I
Series B Preferred SharesF1,F7—Oct 24, 2016C5,774D——Common Stock5,7740I

Explanation of responses

Remarks

This amendment is being filed solely to report the conversion of preferred stock into common stock that occurred upon the closing of the Issuer's initial public offering (the "IPO") on October 24, 2016, which conversion was inadvertently omitted from the original Form 4 filed on October 26, 2016, and to correct the transaction code for the purchases in the IPO, which was previously reported as "A," and not to report any other transactions in securities of the Issuer.